Exploration of Targeted Anti-tumor Therapy

Table 1. Definition of oligoprogressive disease.

Question	Main responses	Consensus status
Is oligoprogressive disease correctly defined as progression in a limited number of lesions, with control over the others?	Yes: 10 (100%)	Consensus
What number of progressive lesions is acceptable for oligoprogressive disease?	≤ 5 lesions: 5 (50%) Any number amenable to local therapy: 5 (50%)	No consensus
Should oligoprogressive disease only occur during effective systemic therapy, or also at primary progression?	Both scenarios: 8 (80%) Only during effective therapy: 2 (20%)	Consensus
Does localization of metastases affect oligoprogressive disease definition?	Not relevant: 8 (80%) Relevant: 2 (20%)	Consensus
Does lesion size matter for oligoprogressive disease definition?	Not relevant: 10 (100%)	Consensus
Should oligoprogressive lesions be measurable according to RECIST 1.1 criteria?	Not required: 6 (60%) Required: 4 (40%)	Relative agreement

Return to article view

RECIST: Response Evaluation Criteria in Solid Tumors.

Declarations

Acknowledgments

The consensus committee would like to thank all the experts who took part in developing the consensus.

Author contributions

DK: Supervision, Writing—original draft, Project administration, Investigation. IO: Investigation, Writing—review & editing. SK: Investigation, Writing—review & editing. NO: Investigation, Writing—review & editing. MD: Investigation, Writing—review & editing. EU: Investigation, Writing—review & editing. DA: Investigation, Writing—review & editing. BB: Investigation, Writing—review & editing. IT: Supervision, Writing—original draft, Project administration, Investigation. TM: Supervision, Writing—original draft, Project administration, Investigation. All authors, as committee members, participated in the preparation of the meeting results questionnaire, data discussion, and article approval.

Conflicts of interest

The authors have no conflicts of interest.

Ethical approval

This study was based exclusively on an anonymous survey of expert opinions and did not involve human participants, patient data, biological specimens, or animal research. Therefore, institutional review board (IRB) or ethics committee (Asfendiyarov Kazakh National Medical University) approval was not required under applicable national regulations.

Consent to participate

Informed consent (including for publication) was obtained from all individual participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Funding

The work was carried out within the framework of the budgetary funding of the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan [BR24992933] “Development and Implementation of Diagnostic Models, Treatment, and Rehabilitation Techniques for Cancer Patients.” The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38:2830–8. [DOI] [PubMed] [PMC]

Tsimafeyeu I, Dengina N, Mitin T. A randomized phase 2 study of the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with metastatic urothelial carcinoma and oligoprogression on maintenance therapy with avelumab (VOLGA 2). J Clin Oncol. 2025;43:TPS4620. [DOI]

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, et al. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. Eur Urol. 2014;66:936–48. [DOI] [PubMed] [PMC]

Chroni A, Miura S, Hamilton L, Vu T, Gaffney SG, Aly V, et al. Clone Phylogenetics Reveals Metastatic Tumor Migrations, Maps, and Models. Cancers. 2022;14:4326. [DOI] [PubMed] [PMC]

Tsimafeyeu I, Guliyev F, Ongarbayev B, Musaeva G, Abdrakhmanov R, Chubenko V, et al. Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma. Urol Oncol: Semin Orig Investig. 2026;44:110989. [DOI] [PubMed]

Tsimafeyeu I, Makhov P, Ovcharenko D, Smith J, Khochenkova Y, Olshanskaya A, et al. A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models. Immuno-Oncol Technol. 2024;23:100725. [DOI] [PubMed] [PMC]

Imano N. Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives. Int J Clin Oncol. 2025;30:1505–21. [DOI] [PubMed]

Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023;184:109681. [DOI] [PubMed]

Dengina N, Mitin T, Gamayunov S, Safina S, Kreinina Y, Tsimafeyeu I. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. ESMO Open. 2019;4:e000535. [DOI] [PubMed] [PMC]

10.

Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022;40:1007. [DOI]

11.

Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023;13:393–412. [DOI] [PubMed]

12.

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. [DOI] [PubMed]

13.

Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, et al. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. Lancet Oncol. 2024;25:e193–e204. [DOI] [PubMed]

14.

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. [DOI] [PubMed] [PMC]

15.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, et al. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Curr Oncol. 2019;26:e81–e93. [DOI] [PubMed] [PMC]

16.

Radiation Oncology Physician Branch, Chinese Medical Doctor Association; Radiation Oncology Branch, Chinese Medical Association; Professional Commitee of Radiation Oncology, China Anti-Cancer Association; Expert Committee of Esophageal Cancer, Chinese Cancer Radiotherapy Alliance; Radiotherapy Sub-Committee, Professional Commitee of Elderly Oncology, Gerontological Society of China. Expert consensus on radiotherapy for oligometastatic esophageal cancer (2025 edition). Radiat Med Prot. 2025;6:119–31. [DOI]